Rosen Law Firm files securities fraud lawsuit against Unicycive Therapeutics
Rosen Law Firm has initiated a class action lawsuit for purchasers of Unicycive Therapeutics, Inc. securities. The suit alleges the company and its management provided misleading information regarding its treatment development.
CITY NEWS, September 8, 2026 – Global investor rights law firm Rosen Law Firm has announced the filing of a class action lawsuit against Unicycive Therapeutics, Inc. (NASDAQ: UNCY). The suit is on behalf of purchasers of the company's securities between December 29, 2025, and June 29, 2026, inclusive.
The lawsuit claims that Unicycive Therapeutics and its executives made materially false and misleading statements to investors. Specifically, the allegations focus on the company's disclosures concerning the status of its investigational treatment and its future prospects.
According to the complaint, the company failed to disclose significant risks associated with the clinical trials and regulatory path for its experimental therapy. This alleged failure to disclose has been claimed to have negatively impacted the stock price, causing financial losses for investors.
Rosen Law Firm is encouraging investors who purchased Unicycive Therapeutics securities during the specified period and suffered losses to contact the firm. The firm aims to recover damages on behalf of the affected investors.